Friday, October 7, 2016

Cosopt


Cosopt is a brand name of dorzolamide/timolol ophthalmic, approved by the FDA in the following formulation(s):


COSOPT (dorzolamide hydrochloride; timolol maleate - solution/drops; ophthalmic)



  • Manufacturer: MERCK

    Approval date: April 7, 1998

    Strength(s): EQ 2% BASE;EQ 0.5% BASE [RLD][AT]

Has a generic version of Cosopt been approved?


Yes. The following products are equivalent to Cosopt:


DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE (dorzolamide hydrochloride; timolol maleate solution/drops; ophthalmic)



  • Manufacturer: ALCON RES

    Approval date: November 18, 2009

    Strength(s): EQ 2% BASE;EQ 0.5% BASE [AT]


  • Manufacturer: APOTEX INC

    Approval date: October 28, 2008

    Strength(s): EQ 2% BASE;EQ 0.5% BASE [AT]


  • Manufacturer: BAUSCH AND LOMB

    Approval date: July 14, 2009

    Strength(s): EQ 2% BASE;EQ 0.5% BASE [AT]


  • Manufacturer: HI TECH PHARMA

    Approval date: October 28, 2008

    Strength(s): EQ 2% BASE;EQ 0.5% BASE [AT]


  • Manufacturer: SANDOZ

    Approval date: November 6, 2008

    Strength(s): EQ 2% BASE;EQ 0.5% BASE [AT]


  • Manufacturer: TEVA PARNTL

    Approval date: September 28, 2009

    Strength(s): EQ 2% BASE;EQ 0.5% BASE [AT]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Cosopt. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents

There are no current U.S. patents associated with Cosopt.

See also...

  • Cosopt Consumer Information (Drugs.com)
  • Cosopt Drops Consumer Information (Wolters Kluwer)
  • Cosopt Consumer Information (Cerner Multum)
  • Cosopt Advanced Consumer Information (Micromedex)
  • Cosopt Ocumeter Advanced Consumer Information (Micromedex)
  • Cosopt Ocumeter Plus Advanced Consumer Information (Micromedex)
  • Dorzolamide/Timolol Drops Consumer Information (Wolters Kluwer)
  • Dorzolamide and timolol ophthalmic Consumer Information (Cerner Multum)
  • Dorzolamide and timolol Ophthalmic Advanced Consumer Information (Micromedex)

Cortifoam


Cortifoam is a brand name of hydrocortisone, approved by the FDA in the following formulation(s):


CORTIFOAM (hydrocortisone acetate - aerosol, metered; rectal)



  • Manufacturer: MEDA PHARMS

    Approval date: February 10, 1982

    Strength(s): 10% [RLD]

Has a generic version of Cortifoam been approved?


No. There is currently no therapeutically equivalent version of Cortifoam available.


Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Cortifoam. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents

There are no current U.S. patents associated with Cortifoam.

See also...

  • Cortifoam foam, enema Consumer Information (Cerner Multum)
  • Hydrocortisone Consumer Information (Wolters Kluwer)
  • Hydrocortisone Enema Consumer Information (Wolters Kluwer)
  • Hydrocortisone Solution Consumer Information (Wolters Kluwer)
  • Hydrocortisone Consumer Information (Cerner Multum)
  • Hydrocortisone rectal foam, enema Consumer Information (Cerner Multum)
  • Hydrocortisone AHFS DI Monographs (ASHP)
  • Hydrocortisone Acetate AHFS DI Monographs (ASHP)
  • Hydrocortisone Sodium Phosphate AHFS DI Monographs (ASHP)
  • Hydrocortisone Sodium Succinate AHFS DI Monographs (ASHP)

Cortisporin Otic


Cortisporin Otic is a brand name of hydrocortisone/neomycin/polymyxin b otic, approved by the FDA in the following formulation(s):


CORTISPORIN (hydrocortisone; neomycin sulfate; polymyxin b sulfate - solution/drops; otic)



  • Manufacturer: MONARCH PHARMS

    Approved Prior to Jan 1, 1982

    Strength(s): 1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML [RLD][AT]

Has a generic version of Cortisporin Otic been approved?


Yes. The following products are equivalent to Cortisporin Otic:


NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE (hydrocortisone; neomycin sulfate; polymyxin b sulfate solution/drops; otic)



  • Manufacturer: ALCON

    Approval date: August 25, 1983

    Strength(s): 1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML [AT]


  • Manufacturer: BAUSCH AND LOMB

    Approval date: December 29, 1995

    Strength(s): 1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML [AT]


  • Manufacturer: LUITPOLD

    Approval date: October 31, 2005

    Strength(s): 1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML [AT]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Cortisporin Otic. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents

There are no current U.S. patents associated with Cortisporin Otic.

See also...

  • Cortisporin Solution Consumer Information (Wolters Kluwer)
  • Cortisporin Suspension Consumer Information (Wolters Kluwer)
  • Cortisporin Otic Consumer Information (Cerner Multum)
  • Cortisporin Otic Advanced Consumer Information (Micromedex)
  • Hydrocortisone/Neomycin/Polymyxin B Solution Consumer Information (Wolters Kluwer)
  • Hydrocortisone/Neomycin/Polymyxin B Suspension Consumer Information (Wolters Kluwer)
  • Hydrocortisone, neomycin, and polymyxin B otic Consumer Information (Cerner Multum)
  • Antibiotic Otic Advanced Consumer Information (Micromedex)
  • Neomycin, polymyxin b, and hydrocortisone Otic Advanced Consumer Information (Micromedex)

Cyklokapron


Cyklokapron is a brand name of tranexamic acid, approved by the FDA in the following formulation(s):


CYKLOKAPRON (tranexamic acid - injectable; injection)



  • Manufacturer: PHARMACIA AND UPJOHN

    Approval date: December 30, 1986

    Strength(s): 100MG/ML [RLD][AP]

Has a generic version of Cyklokapron been approved?


Yes. The following products are equivalent to Cyklokapron:


tranexamic acid injectable; injection



  • Manufacturer: MYLAN INSTITUTIONAL

    Approval date: November 3, 2011

    Strength(s): 100MG/ML [AP]


  • Manufacturer: PHARMAFORCE

    Approval date: August 10, 2011

    Strength(s): 100MG/ML [AP]


  • Manufacturer: VERSAPHARM INC

    Approval date: November 17, 2011

    Strength(s): 100MG/ML [AP]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Cyklokapron. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents

There are no current U.S. patents associated with Cyklokapron.

See also...

  • Cyklokapron Consumer Information (Wolters Kluwer)
  • Cyklokapron Tablet Consumer Information (Wolters Kluwer)
  • Cyklokapron Consumer Information (Cerner Multum)
  • Cyklokapron Advanced Consumer Information (Micromedex)
  • Tranexamic Acid Consumer Information (Wolters Kluwer)
  • Tranexamic Acid Tablet Consumer Information (Wolters Kluwer)
  • Tranexamic acid Consumer Information (Cerner Multum)
  • Tranexamic acid Advanced Consumer Information (Micromedex)
  • Tranexamic acid Intravenous Advanced Consumer Information (Micromedex)

Copegus


Copegus is a brand name of ribavirin, approved by the FDA in the following formulation(s):


COPEGUS (ribavirin - tablet; oral)



  • Manufacturer: ROCHE

    Approval date: December 3, 2002

    Strength(s): 200MG [AB]

Has a generic version of Copegus been approved?


A generic version of Copegus has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Copegus and have been approved by the FDA:


ribavirin tablet; oral



  • Manufacturer: AUROBINDO PHARMA

    Approval date: September 17, 2009

    Strength(s): 200MG [AB]


  • Manufacturer: SANDOZ

    Approval date: October 3, 2006

    Strength(s): 200MG [AB]


  • Manufacturer: TEVA

    Approval date: December 5, 2005

    Strength(s): 200MG [AB]


  • Manufacturer: THREE RIVERS PHARMS

    Approval date: December 5, 2005

    Strength(s): 200MG [AB]


  • Manufacturer: ZYDUS PHARMS USA

    Approval date: December 5, 2005

    Strength(s): 200MG [AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Copegus. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents

There are no current U.S. patents associated with Copegus.

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:
    • August 9, 2014 - NEW PATIENT POPULATION

See also...

  • Copegus Consumer Information (Wolters Kluwer)
  • Copegus Consumer Information (Cerner Multum)
  • Copegus Advanced Consumer Information (Micromedex)
  • Ribavirin Consumer Information (Wolters Kluwer)
  • Ribavirin Capsules Consumer Information (Wolters Kluwer)
  • Ribavirin Solution Consumer Information (Wolters Kluwer)
  • Ribavirin Consumer Information (Cerner Multum)
  • Ribasphere Ribapak Advanced Consumer Information (Micromedex)
  • Ribavirin Advanced Consumer Information (Micromedex)
  • Ribavirin Inhalation, oral/nebulization Advanced Consumer Information (Micromedex)
  • Ribavirin AHFS DI Monographs (ASHP)

Cordarone


Cordarone is a brand name of amiodarone, approved by the FDA in the following formulation(s):


CORDARONE (amiodarone hydrochloride - tablet; oral)



  • Manufacturer: WYETH PHARMS INC

    Approval date: December 24, 1985

    Strength(s): 200MG [RLD][AB]

Has a generic version of Cordarone been approved?


Yes. The following products are equivalent to Cordarone:


amiodarone hydrochloride tablet; oral



  • Manufacturer: APOTEX CORP

    Approval date: November 6, 2008

    Strength(s): 200MG [AB]


  • Manufacturer: AUROSAL PHARMS

    Approval date: April 8, 2005

    Strength(s): 200MG [AB]


  • Manufacturer: BARR

    Approval date: January 25, 2001

    Strength(s): 200MG [AB]


  • Manufacturer: MYLAN

    Approval date: February 24, 1999

    Strength(s): 200MG [AB]


  • Manufacturer: SANDOZ

    Approval date: December 23, 1998

    Strength(s): 200MG [AB]


  • Manufacturer: TARO

    Approval date: March 30, 2001

    Strength(s): 200MG [AB]


  • Manufacturer: TEVA PHARMS

    Approval date: November 30, 1998

    Strength(s): 200MG [AB]


  • Manufacturer: ZYDUS PHARMS USA INC

    Approval date: September 16, 2008

    Strength(s): 200MG [AB]

PACERONE (amiodarone hydrochloride tablet; oral)



  • Manufacturer: UPSHER SMITH

    Approval date: April 30, 1998

    Strength(s): 200MG [AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Cordarone. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents

There are no current U.S. patents associated with Cordarone.

See also...

  • Cordarone Consumer Information (Wolters Kluwer)
  • Cordarone Consumer Information (Cerner Multum)
  • Cordarone Advanced Consumer Information (Micromedex)
  • Amiodarone Consumer Information (Drugs.com)
  • Amiodarone Consumer Information (Wolters Kluwer)
  • Amiodarone Solution Consumer Information (Wolters Kluwer)
  • Amiodarone Consumer Information (Cerner Multum)
  • Amiodarone injection Consumer Information (Cerner Multum)
  • Amiodarone Intravenous Advanced Consumer Information (Micromedex)
  • Amiodarone Intravenous, Oral Advanced Consumer Information (Micromedex)
  • Amiodarone Hydrochloride AHFS DI Monographs (ASHP)

Cozaar


Cozaar is a brand name of losartan, approved by the FDA in the following formulation(s):


COZAAR (losartan potassium - tablet; oral)



  • Manufacturer: MERCK

    Approval date: April 14, 1995

    Strength(s): 25MG [AB], 50MG [AB]


  • Manufacturer: MERCK

    Approval date: October 13, 1998

    Strength(s): 100MG [RLD][AB]

Has a generic version of Cozaar been approved?


Yes. The following products are equivalent to Cozaar:


losartan potassium tablet; oral



  • Manufacturer: ACTAVIS INC

    Approval date: October 6, 2010

    Strength(s): 100MG [AB], 25MG [AB], 50MG [AB]


  • Manufacturer: ALEMBIC PHARMS LTD

    Approval date: October 6, 2010

    Strength(s): 100MG [AB], 25MG [AB], 50MG [AB]


  • Manufacturer: APOTEX CORP

    Approval date: October 6, 2010

    Strength(s): 100MG [AB], 25MG [AB], 50MG [AB]


  • Manufacturer: AUROBINDO PHARMA

    Approval date: October 6, 2010

    Strength(s): 100MG [AB], 25MG [AB], 50MG [AB]


  • Manufacturer: LUPIN LTD

    Approval date: October 6, 2010

    Strength(s): 100MG [AB], 25MG [AB], 50MG [AB]


  • Manufacturer: MYLAN

    Approval date: October 6, 2010

    Strength(s): 100MG [AB], 25MG [AB], 50MG [AB]


  • Manufacturer: PRINSTON INC

    Approval date: June 6, 2011

    Strength(s): 100MG [AB], 25MG [AB], 50MG [AB]


  • Manufacturer: ROXANE

    Approval date: October 6, 2010

    Strength(s): 100MG [AB], 25MG [AB], 50MG [AB]


  • Manufacturer: SANDOZ

    Approval date: October 6, 2010

    Strength(s): 100MG [AB], 25MG [AB], 50MG [AB]


  • Manufacturer: TEVA

    Approval date: April 6, 2010

    Strength(s): 100MG [AB], 25MG [AB], 50MG [AB]


  • Manufacturer: TORRENT PHARMS

    Approval date: October 6, 2010

    Strength(s): 100MG [AB], 25MG [AB], 50MG [AB]


  • Manufacturer: UPSHER SMITH

    Approval date: October 6, 2010

    Strength(s): 100MG [AB], 25MG [AB], 50MG [AB]


  • Manufacturer: WATSON LABS

    Approval date: October 6, 2010

    Strength(s): 100MG [AB], 25MG [AB], 50MG [AB]


  • Manufacturer: ZYDUS PHARMS USA INC

    Approval date: October 6, 2010

    Strength(s): 100MG [AB], 25MG [AB], 50MG [AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Cozaar. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents

There are no current U.S. patents associated with Cozaar.

See also...

  • Cozaar Consumer Information (Drugs.com)
  • Cozaar Consumer Information (Wolters Kluwer)
  • Cozaar Consumer Information (Cerner Multum)
  • Cozaar Advanced Consumer Information (Micromedex)
  • Cozaar AHFS DI Monographs (ASHP)
  • Losartan Consumer Information (Wolters Kluwer)
  • Losartan Consumer Information (Cerner Multum)
  • Losartan Advanced Consumer Information (Micromedex)
  • Losartan Potassium AHFS DI Monographs (ASHP)

Cystadane


Cystadane is a brand name of betaine, approved by the FDA in the following formulation(s):


CYSTADANE (betaine hydrochloride - for solution; oral)



  • Manufacturer: RARE DIS THERAP

    Approval date: October 25, 1996

    Strength(s): 1GM/SCOOPFUL [RLD]

Has a generic version of Cystadane been approved?


No. There is currently no therapeutically equivalent version of Cystadane available.


Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Cystadane. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents

There are no current U.S. patents associated with Cystadane.

See also...

  • Cystadane Powder Consumer Information (Wolters Kluwer)
  • Cystadane Consumer Information (Cerner Multum)
  • Cystadane Advanced Consumer Information (Micromedex)
  • Betaine Powder Consumer Information (Wolters Kluwer)
  • Betaine Consumer Information (Cerner Multum)
  • Betaine Advanced Consumer Information (Micromedex)

Thursday, October 6, 2016

Cordran


See also: Generic Cordran SP


Cordran is a brand name of flurandrenolide topical, approved by the FDA in the following formulation(s):


CORDRAN (flurandrenolide - lotion; topical)



  • Manufacturer: WATSON LABS

    Approved Prior to Jan 1, 1982

    Strength(s): 0.05% [RLD]

CORDRAN (flurandrenolide - tape; topical)



  • Manufacturer: WATSON PHARMS

    Approved Prior to Jan 1, 1982

    Strength(s): 0.004MG/SQ CM [RLD]

Has a generic version of Cordran been approved?


No. There is currently no therapeutically equivalent version of Cordran available.


Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Cordran. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents

There are no current U.S. patents associated with Cordran.

See also...

  • Cordran Cream Consumer Information (Wolters Kluwer)
  • Cordran Lotion Consumer Information (Wolters Kluwer)
  • Cordran Consumer Information (Cerner Multum)
  • Cordran Advanced Consumer Information (Micromedex)
  • Cordran AHFS DI Monographs (ASHP)
  • Flurandrenolide Cream Consumer Information (Wolters Kluwer)
  • Flurandrenolide Lotion Consumer Information (Wolters Kluwer)
  • Flurandrenolide Tape Consumer Information (Wolters Kluwer)
  • Flurandrenolide topical Consumer Information (Cerner Multum)
  • Drenison Advanced Consumer Information (Micromedex)
  • Drenison 1/4 Advanced Consumer Information (Micromedex)
  • Drenison Tape Advanced Consumer Information (Micromedex)
  • Flurandrenolide Topical application Advanced Consumer Information (Micromedex)
  • Flurandrenolide AHFS DI Monographs (ASHP)

Cutivate


Cutivate is a brand name of fluticasone topical, approved by the FDA in the following formulation(s):


CUTIVATE (fluticasone propionate - cream; topical)



  • Manufacturer: FOUGERA PHARMS

    Approval date: December 18, 1990

    Strength(s): 0.05% [RLD][AB]

CUTIVATE (fluticasone propionate - lotion; topical)



  • Manufacturer: FOUGERA PHARMS

    Approval date: March 31, 2005

    Strength(s): 0.05% [RLD][AB]

CUTIVATE (fluticasone propionate - ointment; topical)



  • Manufacturer: FOUGERA PHARMS

    Approval date: December 14, 1990

    Strength(s): 0.005% [RLD][AB]

Has a generic version of Cutivate been approved?


A generic version of Cutivate has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Cutivate and have been approved by the FDA:


fluticasone propionate cream; topical



  • Manufacturer: G AND W LABS

    Approval date: June 30, 2006

    Strength(s): 0.05% [AB]


  • Manufacturer: NESHER PHARMS

    Approval date: September 10, 2004

    Strength(s): 0.05% [AB]


  • Manufacturer: PERRIGO NEW YORK

    Approval date: May 14, 2004

    Strength(s): 0.05% [AB]


  • Manufacturer: TOLMAR

    Approval date: May 14, 2004

    Strength(s): 0.05% [AB]

fluticasone propionate lotion; topical



  • Manufacturer: GLENMARK GENERICS

    Approval date: May 2, 2011

    Strength(s): 0.05% [AB]

fluticasone propionate ointment; topical



  • Manufacturer: G AND W LABS

    Approval date: March 3, 2006

    Strength(s): 0.005% [AB]


  • Manufacturer: PERRIGO NEW YORK

    Approval date: May 14, 2004

    Strength(s): 0.005% [AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Cutivate. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents


Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.




  • Fluticasone lotion having improved vasoconstrictor activity
    Patent 7,300,669
    Issued: November 27, 2007
    Inventor(s): Dow; Gordon J. & Johnson; Keith Arthur & Kelly; Frances Furr & Lathrop; Robert William & Rajagopalan; Rukmini
    Assignee(s): Altana Inc.
    A fluticasone lotion having improved vasoconstrictor and anti-inflammatory activity and higher than expected potency. The fluticasone lotion contains 0.05 weight percent fluticasone propionate and an oil-in-water vehicle that includes excipients. The fluticasone lotion is unexpectedly efficacious while exhibiting an improved safety profile.
    Patent expiration dates:

    • October 20, 2019
      ✓ 
      Patent use: RELIEF OF THE INFLAMMATORY AND PRURITIC MANIFESTATIONS OF ATOPIC DERMATITIS IN PATIENTS ONE YEAR OF AGE OR OLDER
      ✓ 
      Drug product



See also...

  • Cutivate Cream Consumer Information (Wolters Kluwer)
  • Cutivate Lotion Consumer Information (Wolters Kluwer)
  • Cutivate Consumer Information (Cerner Multum)
  • Cutivate Advanced Consumer Information (Micromedex)
  • Fluticasone Cream Consumer Information (Wolters Kluwer)
  • Fluticasone Lotion Consumer Information (Wolters Kluwer)
  • Fluticasone topical Consumer Information (Cerner Multum)
  • Fluticasone Topical application Advanced Consumer Information (Micromedex)

Cuprimine


Cuprimine is a brand name of penicillamine, approved by the FDA in the following formulation(s):


CUPRIMINE (penicillamine - capsule; oral)



  • Manufacturer: ATON

    Approved Prior to Jan 1, 1982

    Strength(s): 250MG [RLD]

Has a generic version of Cuprimine been approved?


No. There is currently no therapeutically equivalent version of Cuprimine available.


Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Cuprimine. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents

There are no current U.S. patents associated with Cuprimine.

See also...

  • Cuprimine Consumer Information (Wolters Kluwer)
  • Cuprimine Consumer Information (Cerner Multum)
  • Cuprimine Advanced Consumer Information (Micromedex)
  • Penicillamine Consumer Information (Wolters Kluwer)
  • Penicillamine Consumer Information (Cerner Multum)
  • Penicillamine Advanced Consumer Information (Micromedex)
  • Penicillamine AHFS DI Monographs (ASHP)

Coumadin


Coumadin is a brand name of warfarin, approved by the FDA in the following formulation(s):


COUMADIN (warfarin sodium - injectable; injection)



  • Manufacturer: BRISTOL MYERS SQUIBB

    Approval date: February 7, 1995

    Strength(s): 5MG/VIAL [RLD]

COUMADIN (warfarin sodium - tablet; oral)



  • Manufacturer: BRISTOL MYERS SQUIBB

    Approved Prior to Jan 1, 1982

    Strength(s): 10MG [RLD][AB], 2.5MG [AB], 2MG [AB], 5MG [AB], 7.5MG [AB]


  • Manufacturer: BRISTOL MYERS SQUIBB

    Approval date: March 1, 1990

    Strength(s): 1MG [AB]


  • Manufacturer: BRISTOL MYERS SQUIBB

    Approval date: August 24, 1993

    Strength(s): 4MG [AB]


  • Manufacturer: BRISTOL MYERS SQUIBB

    Approval date: November 18, 1996

    Strength(s): 3MG [AB], 6MG [AB]

Has a generic version of Coumadin been approved?


Yes. The following products are equivalent to Coumadin:


JANTOVEN (warfarin sodium tablet; oral)



  • Manufacturer: USL PHARMA

    Approval date: October 2, 2003

    Strength(s): 10MG [AB], 1MG [AB], 2.5MG [AB], 2MG [AB], 3MG [AB], 4MG [AB], 5MG [AB], 6MG [AB], 7.5MG [AB]

warfarin sodium tablet; oral



  • Manufacturer: BARR

    Approval date: March 26, 1997

    Strength(s): 10MG [AB], 1MG [AB], 2.5MG [AB], 2MG [AB], 4MG [AB], 5MG [AB], 7.5MG [AB]


  • Manufacturer: BARR

    Approval date: November 5, 1998

    Strength(s): 3MG [AB], 6MG [AB]


  • Manufacturer: INVAGEN PHARMS

    Approval date: May 25, 2011

    Strength(s): 10MG [AB], 1MG [AB], 2.5MG [AB], 2MG [AB], 3MG [AB], 4MG [AB], 5MG [AB], 6MG [AB], 7.5MG [AB]


  • Manufacturer: MYLAN

    Approval date: September 27, 2004

    Strength(s): 10MG [AB], 1MG [AB], 2MG [AB], 3MG [AB], 4MG [AB], 5MG [AB], 6MG [AB], 7.5MG [AB]


  • Manufacturer: MYLAN

    Approval date: September 29, 2004

    Strength(s): 2.5MG [AB]


  • Manufacturer: PLIVA

    Approval date: July 5, 2006

    Strength(s): 10MG [AB], 1MG [AB], 2.5MG [AB], 2MG [AB], 3MG [AB], 4MG [AB], 5MG [AB], 6MG [AB], 7.5MG [AB]


  • Manufacturer: TARO

    Approval date: July 15, 1999

    Strength(s): 10MG [AB], 1MG [AB], 2.5MG [AB], 2MG [AB], 3MG [AB], 4MG [AB], 5MG [AB], 6MG [AB], 7.5MG [AB]


  • Manufacturer: ZYDUS PHARMS USA

    Approval date: May 30, 2006

    Strength(s): 10MG [AB], 1MG [AB], 2.5MG [AB], 2MG [AB], 3MG [AB], 4MG [AB], 5MG [AB], 6MG [AB], 7.5MG [AB]

Note: No generic formulation of the following product is available.


  • warfarin sodium - injectable; injection

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Coumadin. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents

There are no current U.S. patents associated with Coumadin.

See also...

  • Coumadin Consumer Information (Drugs.com)
  • Coumadin Consumer Information (Wolters Kluwer)
  • Coumadin Tablets Consumer Information (Wolters Kluwer)
  • Coumadin Consumer Information (Cerner Multum)
  • Coumadin Advanced Consumer Information (Micromedex)
  • Coumadin Intravenous Advanced Consumer Information (Micromedex)
  • Coumadin AHFS DI Monographs (ASHP)
  • Warfarin Consumer Information (Drugs.com)
  • Warfarin Consumer Information (Wolters Kluwer)
  • Warfarin Tablets Consumer Information (Wolters Kluwer)
  • Warfarin Consumer Information (Cerner Multum)
  • Warfarin Advanced Consumer Information (Micromedex)
  • Warfarin Intravenous Advanced Consumer Information (Micromedex)
  • Warfarin Sodium AHFS DI Monographs (ASHP)

Cytomel


Cytomel is a brand name of liothyronine, approved by the FDA in the following formulation(s):


CYTOMEL (liothyronine sodium - tablet; oral)



  • Manufacturer: KING PHARMS

    Approved Prior to Jan 1, 1982

    Strength(s): EQ 0.005MG BASE [AB], EQ 0.025MG BASE [AB], EQ 0.05MG BASE [RLD][AB]

Has a generic version of Cytomel been approved?


Yes. The following products are equivalent to Cytomel:


liothyronine sodium tablet; oral



  • Manufacturer: COASTAL PHARMS

    Approval date: March 20, 2009

    Strength(s): EQ 0.005MG BASE [AB], EQ 0.025MG BASE [AB], EQ 0.05MG BASE [AB]


  • Manufacturer: MYLAN

    Approval date: July 14, 2009

    Strength(s): EQ 0.005MG BASE [AB], EQ 0.025MG BASE [AB], EQ 0.05MG BASE [AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Cytomel. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents

There are no current U.S. patents associated with Cytomel.

See also...

  • Cytomel Consumer Information (Wolters Kluwer)
  • Cytomel Consumer Information (Cerner Multum)
  • Cytomel Advanced Consumer Information (Micromedex)
  • Liothyronine Consumer Information (Wolters Kluwer)
  • Liothyronine Tablets Consumer Information (Wolters Kluwer)
  • Liothyronine Consumer Information (Cerner Multum)
  • Liothyronine Advanced Consumer Information (Micromedex)
  • Liothyronine Intravenous Advanced Consumer Information (Micromedex)
  • Liothyronine Sodium AHFS DI Monographs (ASHP)

Cytovene


Cytovene is a brand name of ganciclovir, approved by the FDA in the following formulation(s):


CYTOVENE (ganciclovir sodium - injectable; injection)



  • Manufacturer: ROCHE PALO

    Approval date: June 23, 1989

    Strength(s): EQ 500MG BASE/VIAL [RLD][AP]

Has a generic version of Cytovene been approved?


Yes. The following products are equivalent to Cytovene:


GANCICLOVIR (ganciclovir sodium injectable; injection)



  • Manufacturer: APP PHARMS

    Approval date: June 21, 2010

    Strength(s): EQ 500MG BASE/VIAL [AP]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Cytovene. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents

There are no current U.S. patents associated with Cytovene.

See also...

  • Cytovene Consumer Information (Wolters Kluwer)
  • Cytovene Capsules Consumer Information (Wolters Kluwer)
  • Cytovene oral and injectable Consumer Information (Cerner Multum)
  • Cytovene Advanced Consumer Information (Micromedex)
  • Cytovene IV Advanced Consumer Information (Micromedex)
  • Cytovene AHFS DI Monographs (ASHP)
  • Ganciclovir Consumer Information (Wolters Kluwer)
  • Ganciclovir Capsules Consumer Information (Wolters Kluwer)
  • Ganciclovir oral and injectable Consumer Information (Cerner Multum)
  • Ganciclovir Oral, Intravenous Advanced Consumer Information (Micromedex)
  • Ganciclovir Sodium AHFS DI Monographs (ASHP)

Cycloset


Cycloset is a brand name of bromocriptine, approved by the FDA in the following formulation(s):


CYCLOSET (bromocriptine mesylate - tablet; oral)



  • Manufacturer: VEROSCIENCE

    Approval date: May 5, 2009

    Strength(s): EQ 0.8MG BASE [RLD]

Has a generic version of Cycloset been approved?


No. There is currently no therapeutically equivalent version of Cycloset available.


Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Cycloset. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents


Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.




  • Therapeutic process for the treatment of the pathologies of Type II diabetes
    Patent 5,468,755
    Issued: November 21, 1995
    Inventor(s): Cincotta; Anthony H. & Meier; Albert H.
    Assignee(s): The Board of Supervisors of Louisiana State University and Agricultural
    A process for the long term modification and regulation of lipid and carbohydrate metabolism--generally to reduce obesity, insulin resistance, and hyperinsulinemia or hyperglycemia, or both (these are the hallmarks of noninsulin dependent, or Type II diabetes)--by administration (i.e., by oral, sublingual or parenternal administration) to a vertebrate, animal or human, of a dopamine agonist, e.g., bromocriptine. Administration of the bromocriptine is made over a limited period at a time of day dependent on the normal circadian rhythm of insulin resistant and insulin sensitive members of a similar species. Insulin resistance, and hyperinsulinemia and hyperglycemia, or both, can be controlled in humans on a long term basis by such treatment inasmuch as the short term daily administration resets hormonal timing in the neural centers of the brain to produce long term effects.
    Patent expiration dates:

    • November 21, 2012
      ✓ 
      Patent use: IMPROVEMENT OF GLYCEMIC CONTROL IN INDIVIDUALS WITH TYPE 2 DIABETES




  • Accelerated release composition containing bromocriptine
    Patent 5,679,685
    Issued: October 21, 1997
    Inventor(s): Cincotta; Anthony H. & Cincotta, Jr.; Manuel & Pelloni; Christopher Louis & Runice; Christopher Eric & Tigner; Sandra Louise
    Assignee(s): Ergo Science, Incorporated
    Geneva Pharmaceuticals, Inc.
    Disclosed herein is a solid oral dosage form comprising bromocriptine and one or more pharmaceutically acceptable excipients. The oral dosage form has a dissolution rate in excess of 90% in 5 minutes in 500 ml of 0.1N HCl aqueous medium at 37 C and is useful for adjusting the plasma prolactin profile of a patient.
    Patent expiration dates:

    • October 21, 2014
      ✓ 
      Drug product




  • Method for modifying and resetting the bloodstream prolactin levels of a human subject
    Patent 5,716,957
    Issued: February 10, 1998
    Inventor(s): Cincotta; Anthony H. & Meier; Albert H.
    Assignee(s): The Board of Supervisors of Louisiana State and Agricultural and
    Ergo Research Corporation
    A process for the long term modification and regulation of lipid and glucose metabolism--generally to reduce obesity, insulin resistance, and hyperinsulinemia or hyperglycemia, or both (these being the hallmarks of noninsulin dependent, or Type II diabetes)--by administration to a vertebrate, animal or human, of a dopamine agonist and a prolactin stimulator. The dopamine agonist and prolactin stimulator are administered in daily dosages, respectively, at a time of day dependent on the normal circadian rhythm of fat and lean members of a similar species. Decreases in body fat deposits result by treatment of an obese species on a daily timed sequence based on circadian rhythms of the peak prolactin, or peak prolactin and peak glucocorticosteroid, blood level established for lean insulin sensitive members of a similar species. The dopamine agonist is administered at the time of, or just after the time of peak plasma prolactin concentration found in lean animals of the same species and the prolactin stimulator is administered at a time just before the plasma prolactin rhythm reaches its peak in lean animals. Insulin resistance, and hyperinsulinemia or hyperglycemia, or both, can also be controlled in humans on a long term basis by treatment corresponding to that of the treatment for obesity. The short term daily injections reset hormonal timing in the neural centers of the brain to produce long term effects.
    Patent expiration dates:

    • February 10, 2015
      ✓ 
      Patent use: IMPROVEMENT OF GLYCEMIC CONTROL IN INDIVIDUALS WITH TYPE 2 DIABETES




  • Therapeutic process for the treatment of the pathologies of type II diabetes
    Patent 5,756,513
    Issued: May 26, 1998
    Inventor(s): Cincotta; Anthony H. & Meier; Albert H.
    Assignee(s): The Board of Supervisors of Louisiana State University and Agricultural
    A process for the long term modification and regulation of lipid and carbohydrate metabolism--generally to reduce obesity, insulin resistance, and hyperinsulinemia or hyperglycemia, or both (these are the hallmarks of noninsulin dependent, or Type II diabetes)--by administration (i.e., by oral, sublingual or parenternal administration) to a vertebrate, animal or human, of a dopamine agonist, e.g., bromocriptine. Administration of the bromocriptine is made over a limited period at a time of day dependent on the normal circadian rhythm of insulin resistant and insulin sensitive members of a similar species. Insulin resistance, and hyperinsulinemia and hyperglycemia, or both, can be controlled in humans on a long term basis by such treatment inasmuch as the short term daily administration resets hormonal timing in the neural centers of the brain to produce long term effects.
    Patent expiration dates:

    • November 21, 2012
      ✓ 
      Patent use: IMPROVEMENT OF GLYCEMIC CONTROL IN INDIVIDUALS WITH TYPE 2 DIABETES




  • Therapeutic process for the treatment of the pathologies of type II diabetes
    Patent 5,866,584
    Issued: February 2, 1999
    Inventor(s): Cincotta; Anthony H. & Meier; Albert H.
    Assignee(s): The Board of Supervisors of Louisiana State University and Agricultural
    A process for the long term modification and regulation of lipid and carbohydrate metabolism--generally to reduce obesity, insulin resistance, and hyperinsulinemia or hyperglycemia, or both (these are the hallmarks of noninsulin dependent, or Type II diabetes)--by administration (i.e., by oral, sublingual or parenternal administration) to a vertebrate, animal or human, of a dopamine agonist, e.g., bromocriptine. Administration of the bromocriptine is made over a limited period at a time of day dependent on the normal circadian rhythm of insulin resistant and insulin sensitive members of a similar species. Insulin resistance, and hyperinsulinemia and hyperglycemia, or both, can be controlled in humans on a long term basis by such treatment inasmuch as the short term, daily administration resets hormonal timing in the neural centers of the brain to produce long term effects.
    Patent expiration dates:

    • November 21, 2012
      ✓ 
      Patent use: IMPROVEMENT OF GLYCEMIC CONTROL IN INDIVIDUALS WITH TYPE 2 DIABETES




  • Methods of identifying responders to dopamine agonist therapy
    Patent 7,888,310
    Issued: February 15, 2011
    Inventor(s): Cincotta; Anthony H.
    The present invention is directed to a method of identifying patients to be treated by dopamine agonist therapy comprising the step of analyzing a plasma or urine sample from said patient for concentrations of norepinephrine (NE), norepinephrine metabolites (NE metabolites), dopamine, dopamine metabolites, serotonin, serotonin metabolites, or fasting triglycerides, wherein one or more of: (a) NE metabolites, (b) NE/NE metabolites: dopamine/dopamine metabolites, (c) NE and serotonin, (d) NE/NE metabolites and serotonin, (e) NE and serotonin metabolites, (f) NE/NE metabolites and serotonin metabolites, or (g) NE is/are greater than about 30% over normal level; or dopamine/dopamine metabolites are less than about 30% below normal; or fasting triglycerides are greater than about 150 mg/dl and/or said patient has blood pressure of greater than about 135/85 mm Hg. The present invention is also directed to treating identified patients with dopamine agonist therapy.
    Patent expiration dates:

    • July 25, 2023
      ✓ 
      Patent use: IMPROVEMENT OF GLYCEMIC CONTROL IN INDIVIDUALS WITH TYPE 2 DIABETES



Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:
    • May 5, 2012 - NEW PRODUCT

See also...

  • Cycloset Consumer Information (Drugs.com)
  • Cycloset Consumer Information (Wolters Kluwer)
  • Cycloset Consumer Information (Cerner Multum)
  • Cycloset Advanced Consumer Information (Micromedex)
  • Bromocriptine Consumer Information (Wolters Kluwer)
  • Bromocriptine Mesylate Consumer Information (Wolters Kluwer)
  • Bromocriptine Consumer Information (Cerner Multum)
  • Bromocriptine Advanced Consumer Information (Micromedex)
  • Bromocriptine Mesylate AHFS DI Monographs (ASHP)

Cortef


See also: Generic Cortenema


Cortef is a brand name of hydrocortisone, approved by the FDA in the following formulation(s):


CORTEF (hydrocortisone - tablet; oral)



  • Manufacturer: PHARMACIA AND UPJOHN

    Approved Prior to Jan 1, 1982

    Strength(s): 10MG [AB], 20MG [RLD][AB], 5MG [AB]

Has a generic version of Cortef been approved?


Yes. The following products are equivalent to Cortef:


hydrocortisone tablet; oral



  • Manufacturer: COREPHARMA

    Approval date: March 30, 2007

    Strength(s): 10MG [AB], 20MG [AB], 5MG [AB]


  • Manufacturer: VINTAGE

    Approval date: July 16, 2007

    Strength(s): 10MG [AB], 20MG [AB], 5MG [AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Cortef. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents

There are no current U.S. patents associated with Cortef.

See also...

  • Cortef Consumer Information (Wolters Kluwer)
  • Cortef Consumer Information (Cerner Multum)
  • Hydrocortisone Consumer Information (Wolters Kluwer)
  • Hydrocortisone Enema Consumer Information (Wolters Kluwer)
  • Hydrocortisone Solution Consumer Information (Wolters Kluwer)
  • Hydrocortisone Consumer Information (Cerner Multum)
  • Hydrocortisone rectal foam, enema Consumer Information (Cerner Multum)
  • Hydrocortisone AHFS DI Monographs (ASHP)
  • Hydrocortisone Acetate AHFS DI Monographs (ASHP)
  • Hydrocortisone Sodium Phosphate AHFS DI Monographs (ASHP)
  • Hydrocortisone Sodium Succinate AHFS DI Monographs (ASHP)

Cytotec


Cytotec is a brand name of misoprostol, approved by the FDA in the following formulation(s):


CYTOTEC (misoprostol - tablet; oral)



  • Manufacturer: GD SEARLE LLC

    Approval date: December 27, 1988

    Strength(s): 0.2MG [RLD][AB]


  • Manufacturer: GD SEARLE LLC

    Approval date: September 21, 1990

    Strength(s): 0.1MG [AB]

Has a generic version of Cytotec been approved?


Yes. The following products are equivalent to Cytotec:


misoprostol tablet; oral



  • Manufacturer: IVAX SUB TEVA PHARMS

    Approval date: July 10, 2002

    Strength(s): 0.1MG [AB], 0.2MG [AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Cytotec. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents

There are no current U.S. patents associated with Cytotec.

See also...

  • Cytotec Consumer Information (Wolters Kluwer)
  • Cytotec Consumer Information (Cerner Multum)
  • Cytotec Advanced Consumer Information (Micromedex)
  • Cytotec AHFS DI Monographs (ASHP)
  • Misoprostol Consumer Information (Wolters Kluwer)
  • Misoprostol Consumer Information (Cerner Multum)
  • Misoprostol Advanced Consumer Information (Micromedex)
  • Misoprostol AHFS DI Monographs (ASHP)

Cyclessa


Cyclessa is a brand name of desogestrel/ethinyl estradiol, approved by the FDA in the following formulation(s):


CYCLESSA (desogestrel; ethinyl estradiol - tablet; oral-28)



  • Manufacturer: ORGANON USA INC

    Approval date: December 20, 2000

    Strength(s): 0.1MG,0.125MG,0.15MG;0.025MG,0.025MG,0.025MG [RLD][AB]

Has a generic version of Cyclessa been approved?


Yes. The following products are equivalent to Cyclessa:


DESOGESTREL AND ETHINYL ESTRADIOL (desogestrel; ethinyl estradiol tablet; oral-28)



  • Manufacturer: WATSON LABS

    Approval date: January 24, 2006

    Strength(s): 0.1MG,0.125MG,0.15MG;0.025MG,0.025MG,0.025MG [AB]

VELIVET (desogestrel; ethinyl estradiol tablet; oral-28)



  • Manufacturer: DURAMED PHARMS BARR

    Approval date: February 24, 2004

    Strength(s): 0.1MG,0.125MG,0.15MG;0.025MG,0.025MG,0.025MG [AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Cyclessa. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents

There are no current U.S. patents associated with Cyclessa.

See also...

  • Cyclessa Consumer Information (Cerner Multum)
  • Desogestrel/Ethinyl Estradiol Consumer Information (Wolters Kluwer)
  • Ethinyl estradiol and desogestrel Consumer Information (Cerner Multum)

Cyanokit


Cyanokit is a brand name of hydroxocobalamin, approved by the FDA in the following formulation(s):


CYANOKIT (hydroxocobalamin - injectable; injection)



  • Manufacturer: MERCK SANTE SAS

    Approval date: April 8, 2011

    Strength(s): 5GM/VIAL (5GM/KIT) [RLD]

Has a generic version of Cyanokit been approved?


No. There is currently no therapeutically equivalent version of Cyanokit available.


Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Cyanokit. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents


Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.




  • Dosage form of hydroxocobalamin and its use in cyanide poisoning
    Patent 5,834,448
    Issued: November 10, 1998
    Inventor(s): Pouchol; Gerard & Bonhomme; Yves & Poulain; Marie-Laure & Duran; Michel
    Assignee(s): Merck Patent Gesellschaft mit beschrankter Haftung
    The invention relates to a new dosage form of hydroxocobalamin which serves in the treatment of cyanide poisoning and contains hydroxocobalamin in freeze-dried form. The hydroxocobalamin is freeze-dried in an acidic medium so as to be practically instantly redissolved in a neutral saline solution. The present invention also relates to a process for producing hydroxocobalamin-based pharmaceutical compositions as well as to first aid kits containing these compositions and methods of using such kits for the treatment of cyanide poisoning.
    Patent expiration dates:

    • November 14, 2016
      ✓ 
      Drug product


    • November 14, 2016
      ✓ 
      Patent use: TREATMENT OF KNOWN OR SUSPECTED CYANIDE POISONING
      ✓ 
      Drug product



Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:
    • December 15, 2013 - ORPHAN DRUG EXCLUSIVITY

See also...

  • Cyanokit Consumer Information (Drugs.com)
  • Cyanokit Kit Consumer Information (Wolters Kluwer)
  • Cyanokit injection Consumer Information (Cerner Multum)
  • Hydroxocobalamin Consumer Information (Wolters Kluwer)
  • Hydroxocobalamin Kit Consumer Information (Wolters Kluwer)
  • Hydroxocobalamin injection Consumer Information (Cerner Multum)

Coreg


See also: Generic Coreg CR


Coreg is a brand name of carvedilol, approved by the FDA in the following formulation(s):


COREG (carvedilol - tablet; oral)



  • Manufacturer: SMITHKLINE BEECHAM

    Approval date: September 14, 1995

    Strength(s): 12.5MG [RLD][AB], 25MG [AB], 6.25MG [AB]


  • Manufacturer: SMITHKLINE BEECHAM

    Approval date: May 29, 1997

    Strength(s): 3.125MG [AB]

Has a generic version of Coreg been approved?


A generic version of Coreg has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Coreg and have been approved by the FDA:


carvedilol tablet; oral



  • Manufacturer: APOTEX INC

    Approval date: September 5, 2007

    Strength(s): 12.5MG [AB], 25MG [AB], 3.125MG [AB], 6.25MG [AB]


  • Manufacturer: AUROBINDO PHARMA

    Approval date: September 5, 2007

    Strength(s): 12.5MG [AB], 25MG [AB], 3.125MG [AB], 6.25MG [AB]


  • Manufacturer: BEXIMCO USA

    Approval date: September 5, 2007

    Strength(s): 12.5MG [AB], 25MG [AB], 3.125MG [AB], 6.25MG [AB]


  • Manufacturer: CARACO

    Approval date: September 5, 2007

    Strength(s): 12.5MG [AB], 25MG [AB], 3.125MG [AB], 6.25MG [AB]


  • Manufacturer: DR REDDYS LABS LTD

    Approval date: September 5, 2007

    Strength(s): 12.5MG [AB], 25MG [AB], 3.125MG [AB], 6.25MG [AB]


  • Manufacturer: GLENMARK GENERICS

    Approval date: September 5, 2007

    Strength(s): 12.5MG [AB], 25MG [AB], 3.125MG [AB], 6.25MG [AB]


  • Manufacturer: HIKMA

    Approval date: September 7, 2007

    Strength(s): 12.5MG [AB], 25MG [AB], 3.125MG [AB], 6.25MG [AB]


  • Manufacturer: LUPIN

    Approval date: September 5, 2007

    Strength(s): 12.5MG [AB], 25MG [AB], 3.125MG [AB], 6.25MG [AB]


  • Manufacturer: MYLAN

    Approval date: September 5, 2007

    Strength(s): 12.5MG [AB], 25MG [AB], 3.125MG [AB], 6.25MG [AB]


  • Manufacturer: PLIVA HRVATSKA DOO

    Approval date: October 30, 2007

    Strength(s): 12.5MG [AB], 25MG [AB], 3.125MG [AB], 6.25MG [AB]


  • Manufacturer: RANBAXY

    Approval date: September 5, 2007

    Strength(s): 12.5MG [AB], 25MG [AB], 3.125MG [AB], 6.25MG [AB]


  • Manufacturer: SANDOZ

    Approval date: September 5, 2007

    Strength(s): 12.5MG [AB], 25MG [AB], 3.125MG [AB], 6.25MG [AB]


  • Manufacturer: TARO

    Approval date: September 5, 2007

    Strength(s): 12.5MG [AB], 25MG [AB], 3.125MG [AB], 6.25MG [AB]


  • Manufacturer: TEVA

    Approval date: September 5, 2007

    Strength(s): 12.5MG [AB], 25MG [AB], 3.125MG [AB], 6.25MG [AB]


  • Manufacturer: WATSON LABS

    Approval date: September 5, 2007

    Strength(s): 12.5MG [AB], 25MG [AB], 3.125MG [AB], 6.25MG [AB]


  • Manufacturer: WOCKHARDT

    Approval date: December 22, 2009

    Strength(s): 12.5MG [AB], 25MG [AB], 3.125MG [AB], 6.25MG [AB]


  • Manufacturer: ZYDUS PHARMS USA INC

    Approval date: September 5, 2007

    Strength(s): 12.5MG [AB], 25MG [AB], 3.125MG [AB], 6.25MG [AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Coreg. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents


Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.




  • Method of treatment for decreasing mortality resulting from congestive heart failure
    Patent RE40000
    Issued: January 8, 2008
    Inventor(s): Lukas-Laskey; Mary Ann & Ruffolo, Jr.; Robert & Shusterman; Neil Howard & Sponer; Gisbert & Strein; Klaus
    Assignee(s): SB Pharmco Puerto Rico Inc.
    A method of treatment using a compound of Formula I: wherein: R1 is hydrogen, lower alkanoyl of up to 6 carbon atoms or aroyl selected from benzoyl and naphthoyl; R2 is hydrogen, lower alkyl of up to 6 carbon atoms or arylalkyl selected from benzyl, phenylethyl and phenylpropyl; R3 is hydrogen or lower alkyl of up to 6 carbon atoms; R4 is hydrogen or lower alkyl of up to 6 carbon atoms, or when X is oxygen, R4 together with R5 can represent —CH2—O—; X is a valency bond, —CH2, oxygen or sulfur; Ar is selected from phenyl, naphthyl, indanyl and tetrahydronapthyl; R5 and R6 are individually selected from hydrogen, fluorine, chlorine, bromine, hydroxyl, lower alkyl of up to 6 carbon atoms, a —CONH2— group, lower alkoxy of up to 6 carbon atoms, benzyloxy, lower alkylthio of up to 6 carbon atoms, lower alkysulphinyl of up to 6 carbon atoms and lower alkylsulphonyl of up to 6 carbon atoms; or R5 and R6 together represent methylenedioxy; or a pharmaceutically acceptable salt thereof, alone or in conjunction with one or more other therapeutic agents, said agents being selected from the group consisting of ACE inhibitors, diuretics, and digoxin for decreasing mortality resulting from congestive heart failure (CHF) in mammals, particularly humans.
    Patent expiration dates:

    • June 7, 2015
      ✓ 
      Patent use: DECREASING MORTALITY CAUSED BY CONGESTIVE HEART FAILURE


    • December 7, 2015
      ✓ 
      Pediatric exclusivity



Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:
    • August 23, 2010 - PEDIATRIC EXCLUSIVITY

See also...

  • Coreg Consumer Information (Drugs.com)
  • Coreg Consumer Information (Wolters Kluwer)
  • Coreg Consumer Information (Cerner Multum)
  • Coreg Advanced Consumer Information (Micromedex)
  • Carvedilol Consumer Information (Wolters Kluwer)
  • Carvedilol Extended-Release Capsules Consumer Information (Wolters Kluwer)
  • Carvedilol Consumer Information (Cerner Multum)
  • Carvedilol Advanced Consumer Information (Micromedex)
  • Carvedilol AHFS DI Monographs (ASHP)

Corzide


Corzide is a brand name of bendroflumethiazide/nadolol, approved by the FDA in the following formulation(s):


CORZIDE (bendroflumethiazide; nadolol - tablet; oral)



  • Manufacturer: KING PHARMS

    Approval date: May 25, 1983

    Strength(s): 5MG;40MG [AB], 5MG;80MG [RLD][AB]

Has a generic version of Corzide been approved?


Yes. The following products are equivalent to Corzide:


NADOLOL AND BENDROFLUMETHAZIDE (bendroflumethiazide; nadolol tablet; oral)



  • Manufacturer: MYLAN

    Approval date: February 15, 2008

    Strength(s): 5MG;40MG [AB], 5MG;80MG [AB]

NADOLOL AND BENDROFLUMETHIAZIDE (bendroflumethiazide; nadolol tablet; oral)



  • Manufacturer: IMPAX LABS

    Approval date: March 30, 2007

    Strength(s): 5MG;40MG [AB], 5MG;80MG [AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Corzide. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents

There are no current U.S. patents associated with Corzide.

See also...

  • Corzide Consumer Information (Wolters Kluwer)
  • Corzide Advanced Consumer Information (Micromedex)
  • Bendroflumethiazide/Nadolol Consumer Information (Wolters Kluwer)
  • Bendroflumethiazide and nadolol Consumer Information (Cerner Multum)
  • Nadolol and bendroflumethiazide Advanced Consumer Information (Micromedex)

Cymbalta


Cymbalta is a brand name of duloxetine, approved by the FDA in the following formulation(s):


CYMBALTA (duloxetine hydrochloride - capsule, delayed rel pellets; oral)



  • Manufacturer: LILLY

    Approval date: August 3, 2004

    Strength(s): EQ 20MG BASE, EQ 30MG BASE, EQ 60MG BASE [RLD]

Has a generic version of Cymbalta been approved?


No. There is currently no therapeutically equivalent version of Cymbalta available.


Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Cymbalta. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents


Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.




  • 3-aryloxy-3-substituted propanamines
    Patent 5,023,269
    Issued: June 11, 1991
    Inventor(s): Robertson; David W. & Wong; David T. & Krushinski, Jr.; Joseph H.
    Assignee(s): Eli Lilly and Company
    The present invention provides 3-aryloxy-3-substituted propanamines capable of inhibiting the uptake of serotonin and norepinephrine.
    Patent expiration dates:

    • June 11, 2013
      ✓ 
      Patent use: METHOD FOR INHIBITING SEROTONIN UPTAKE
      ✓ 
      Drug substance
      ✓ 
      Drug product


    • June 11, 2013
      ✓ 
      Patent use: MANAGEMENT OF FIBROMYALGIA (FM)
      ✓ 
      Drug substance
      ✓ 
      Drug product


    • June 11, 2013
      ✓ 
      Patent use: TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
      ✓ 
      Drug substance
      ✓ 
      Drug product


    • June 11, 2013
      ✓ 
      Patent use: MANAGEMENT OF CHRONIC MUSCULOSKELETAL PAIN
      ✓ 
      Drug substance
      ✓ 
      Drug product


    • June 11, 2013
      ✓ 
      Patent use: METHOD OF TREATING ANXIETY
      ✓ 
      Drug substance
      ✓ 
      Drug product


    • June 11, 2013
      ✓ 
      Patent use: METHOD OF TREATING DEPRESSION
      ✓ 
      Drug substance
      ✓ 
      Drug product


    • June 11, 2013
      ✓ 
      Patent use: METHOD FOR INHIBITING NOREPINEPHRINE UPTAKE
      ✓ 
      Drug substance
      ✓ 
      Drug product


    • June 11, 2013
      ✓ 
      Patent use: TREATMENT OF GENERALIZED ANXIETY DISORDER
      ✓ 
      Drug substance
      ✓ 
      Drug product


    • June 11, 2013
      ✓ 
      Patent use: TREATMENT OF MAJOR DEPRESSIVE DISORDER(MDD);ALTHOUGH THE MEHCHANISM OF THE ANTIDEPRESSANT ACTION OF DULOXETINE IN HUMANS IS UNKNOWN, IT IS BELIEVED TO BE RELATED TO ITS POTENTIATION OF SERATONERGIC AND NORADRENERGIC ACTIVITY IN THE CNS
      ✓ 
      Drug substance
      ✓ 
      Drug product




  • Duloxetine enteric pellets
    Patent 5,508,276
    Issued: April 16, 1996
    Inventor(s): Anderson; Neil R. & Oren; Peter L. & Ogura; Toshihiro & Fujii; Toshiro
    Assignee(s): Eli Lilly and Company
    Shionogi & Co.
    A superior enteric formulation of the antidepressant drug, duloxetine, is in the form of enteric pellets of which the enteric layer comprises hydroxypropylmethylcellulose acetate succinate.
    Patent expiration dates:

    • July 18, 2014
      ✓ 
      Drug product




  • Treatment of fibromyalgia
    Patent 6,596,756
    Issued: July 22, 2003
    Inventor(s): David Joel; Goldstein & Smriti; Iyengar & Rosa Marie Ademe; Simmons
    Assignee(s): Eli Lilly and Company
    A method of using N-methyl-3-(1-naphthalenyloxy)-3-(2-thienyl)propanamine to treat persistent pain.
    Patent expiration dates:

    • September 10, 2019
      ✓ 
      Patent use: MANAGEMENT OF FIBROMYALGIA (FM)



Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:
    • November 28, 2010 - REVISIONS TO PROVIDE FOR RESULTS OF MAINTENANCE DATA IN ADULT PATIENTS WITH MAJOR DEPRESSIVE DISORDER

    • June 13, 2011 - MANAGEMENT OF FIBROMYALGIA

    • November 19, 2012 - MAINTENANCE OF GENERALIZED ANXIETY DISORDER (GAD)

    • November 4, 2013 - MANAGEMENT OF CHRONIC MUSCULOSKELETAL PAIN

See also...

  • Cymbalta Consumer Information (Drugs.com)
  • Cymbalta Delayed-Release Capsules Consumer Information (Wolters Kluwer)
  • Cymbalta Consumer Information (Cerner Multum)
  • Cymbalta Advanced Consumer Information (Micromedex)
  • Cymbalta AHFS DI Monographs (ASHP)
  • Duloxetine Delayed-Release Capsules Consumer Information (Wolters Kluwer)
  • Duloxetine Consumer Information (Cerner Multum)
  • Duloxetine Advanced Consumer Information (Micromedex)
  • Duloxetine AHFS DI Monographs (ASHP)

Cortrosyn


Cortrosyn is a brand name of cosyntropin, approved by the FDA in the following formulation(s):


CORTROSYN (cosyntropin - injectable; injection)



  • Manufacturer: AMPHASTAR PHARMS INC

    Approved Prior to Jan 1, 1982

    Strength(s): 0.25MG/VIAL [RLD][AP]

Has a generic version of Cortrosyn been approved?


Yes. The following products are equivalent to Cortrosyn:


cosyntropin injectable; injection



  • Manufacturer: BIONICHE PHARMA

    Approval date: December 17, 2009

    Strength(s): 0.25MG/VIAL [AP]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Cortrosyn. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents

There are no current U.S. patents associated with Cortrosyn.

See also...

  • Cortrosyn Consumer Information (Wolters Kluwer)
  • Cosyntropin Consumer Information (Wolters Kluwer)

Cordran SP


See also: Generic Cordran


Cordran SP is a brand name of flurandrenolide topical, approved by the FDA in the following formulation(s):


CORDRAN SP (flurandrenolide - cream; topical)



  • Manufacturer: WATSON PHARMS

    Approved Prior to Jan 1, 1982

    Strength(s): 0.025%

Has a generic version of Cordran SP been approved?


No. There is currently no therapeutically equivalent version of Cordran SP available.


Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Cordran SP. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents

There are no current U.S. patents associated with Cordran SP.

See also...

  • Cordran SP Cream Consumer Information (Wolters Kluwer)
  • Cordran SP Consumer Information (Cerner Multum)
  • Cordran SP Advanced Consumer Information (Micromedex)
  • Flurandrenolide Cream Consumer Information (Wolters Kluwer)
  • Flurandrenolide Lotion Consumer Information (Wolters Kluwer)
  • Flurandrenolide Tape Consumer Information (Wolters Kluwer)
  • Flurandrenolide topical Consumer Information (Cerner Multum)
  • Drenison Advanced Consumer Information (Micromedex)
  • Drenison 1/4 Advanced Consumer Information (Micromedex)
  • Drenison Tape Advanced Consumer Information (Micromedex)
  • Flurandrenolide Topical application Advanced Consumer Information (Micromedex)
  • Flurandrenolide AHFS DI Monographs (ASHP)

Crixivan


Crixivan is a brand name of indinavir, approved by the FDA in the following formulation(s):


CRIXIVAN (indinavir sulfate - capsule; oral)



  • Manufacturer: MERCK SHARP DOHME

    Approval date: March 13, 1996

    Strength(s): EQ 200MG BASE, EQ 400MG BASE [RLD]


  • Manufacturer: MERCK SHARP DOHME

    Approval date: April 19, 2000

    Strength(s): EQ 100MG BASE

Has a generic version of Crixivan been approved?


No. There is currently no therapeutically equivalent version of Crixivan available.


Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Crixivan. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents


Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.




  • HIV protease inhibitors useful for the treatment of AIDS
    Patent 5,413,999
    Issued: May 9, 1995
    Inventor(s): Vacca; Joseph P. & Dorsey; Bruce D. & Guare; James P. & Holloway; M. Katharine & Hungate; Randall W. & Levin; Rhonda B.
    Assignee(s): Merck & Co., Inc.
    Compounds of formula ##STR1## where R.sup.1 and R.sup.2 are independently hydrogen or optionally-substituted C.sub.1-4 alkyl or aryl, or R.sup.1 and R.sup.2 are joined together to form a monocyclic or bicyclic ring system, are HIV protease inhibitors. These compounds are useful in the treatment of infection by HIV and in the treatment of AIDS, either as compounds, pharmaceutically acceptable salts, pharmaceutical composition ingredients, whether or not in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of treating AIDS and methods of treating infection by HIV are also described.
    Patent expiration dates:

    • May 9, 2012
      ✓ 
      Patent use: INHIBITING HIV PROTEASE




  • Dry granulation formulation for an HIV protease inhibitor
    Patent 6,645,961
    Issued: November 11, 2003
    Inventor(s): Chung Y.; Lui & Drazen; Ostovic & Ashok V.; Katdare & Christine; Stelmach
    Assignee(s): Merck & Co., Inc.
    This invention relates to a dry granulation capsule formulation of the HIV protease inhibitor, indinavir sulfate, which is useful in the treatment of AIDS, ARC or HIV infection. Processes for making the oral formulation are also disclosed.
    Patent expiration dates:

    • March 4, 2018
      ✓ 
      Drug product




  • Combination therapy for HIV infection
    Patent 6,689,761
    Issued: February 10, 2004
    Inventor(s): Jeffrey A.; Chodakewitz & Emilio A.; Emini
    Assignee(s): Merck & Co., Inc.
    The combination of the HIV protease inhibitor Compound J, 3TC, and, optionally AZT, ddI, or ddC, is useful in the inhibition of HIV protease, the inhibition of HIV reverse transcriptase, the prevention or treatment of infection by HIV and the treatment of AIDS, either as compounds, pharmaceutically acceptable salts, pharmaceutical composition ingredients, whether or not in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of treating AIDS and methods of preventing or treating infection by HIV are also described.
    Patent expiration dates:

    • February 10, 2021
      ✓ 
      Patent use: TREATING HIV INFECTION WITH INDINAVIR SULFATE IN COMBINATION WITH ANTIRETROVIRAL AGENTS



See also...

  • Crixivan Consumer Information (Wolters Kluwer)
  • Crixivan Consumer Information (Cerner Multum)
  • Crixivan Advanced Consumer Information (Micromedex)
  • Crixivan AHFS DI Monographs (ASHP)
  • Indinavir Consumer Information (Wolters Kluwer)
  • Indinavir Consumer Information (Cerner Multum)
  • Indinavir Advanced Consumer Information (Micromedex)
  • Indinavir Sulfate AHFS DI Monographs (ASHP)